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Objective: The prevalence of mitochondrial disease has proven difficult to establish, predominantly as a result of clin-
ical and genetic heterogeneity. The phenotypic spectrum of mitochondrial disease has expanded significantly since
the original reports that associated classic clinical syndromes with mitochondrial DNA (mtDNA) rearrangements and
point mutations. The revolution in genetic technologies has allowed interrogation of the nuclear genome in a manner
that has dramatically improved the diagnosis of mitochondrial disorders. We comprehensively assessed the preva-
lence of all forms of adult mitochondrial disease to include pathogenic mutations in both nuclear and mtDNA.
Methods: Adults with suspected mitochondrial disease in the North East of England were referred to a single neurol-
ogy center from 1990 to 2014. For the midyear period of 2011, we evaluated the minimum prevalence of sympto-
matic nuclear DNA mutations and symptomatic and asymptomatic mtDNA mutations causing mitochondrial diseases.
Results: The minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000), comparable with our
previously published prevalence rates. In this population, nuclear mutations were responsible for clinically overt adult
mitochondrial disease in 2.9 per 100,000 adults.
Interpretation: Combined, our data confirm that the total prevalence of adult mitochondrial disease, including path-
ogenic mutations of both the mitochondrial and nuclear genomes (1 in 4,300), is among the commonest adult
forms of inherited neurological disorders. These figures hold important implications for the evaluation of interven-
tions, provision of evidence-based health policies, and planning of future services.
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Mitochondrial disorders are frequently multisystemicin nature and cause significant morbidity and mor-
tality.1,2 Unfortunately, to date, there are few effective
treatments and no known cure. The overall disease bur-
den is potentially extensive, resulting in substantial direct
and indirect health care costs to the patient and society
as a whole. To date, little is known of the true epidemio-
logical burden of mitochondrial disease. Yet such infor-
mation will have substantial implications for evaluation
of interventions, provision of evidence-based health poli-
cies, and planning of future services for this chronic
condition.
Accurate assessment of mitochondrial disease preva-
lence has proven difficult in the past. Meticulous clinical
and biochemical characterization of patients remains fun-
damental to diagnostic yield. Yet diverse and expanding
clinical features, variable genotype–phenotype correlates,
and the complex structure of referral pathways have all
impeded attempts to gauge the true epidemiological
impact of mitochondrial disease. Recent advances in
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diagnostic techniques in tandem with streamlining of
referral pathways in the United Kingdom and deploy-
ment of extensive family tracing have improved case
ascertainment and permitted, for the first time, recording
of the minimum prevalence of adult mitochondrial dis-
ease, to include pathogenic mutations in both mitochon-
drial DNA (mtDNA) and nuclear DNA (nDNA).
Subjects and Methods
Adult cases (>16 years old) with suspected mitochondrial dis-
ease were ascertained following referral to a single specialist
mitochondrial center in the North East of England between
1990 and 2011. Referral patterns to this center are drawn
mainly from tertiary neurology and neuro-ophthalmology sour-
ces, but historical links with other specialties likely to encounter
mitochondrial disease (diabetes, renal, cardiac, and audiology
clinics) account for other common routes of referral. The New-
castle Mitochondrial Centre is among only 3 highly specialized,
national referral centers for mitochondrial disease in the United
Kingdom.
Those individuals with pathogenic mtDNA or nDNA
mutations, or those with unidentified nuclear mutations, but
pathological multiple mtDNA deletions evident in muscle, who
were alive at the midyear period of 2011, were identified.
Those with multiple mtDNA deletions in muscle were only
included when there was no evidence of other muscle pathol-
ogy, the mtDNA deletions had been independently verified
using 2 different techniques (long-range polymerase chain reac-
tion [PCR], Southern blot or real-time PCR), and the clinical
and biochemical (>3% cyclooxygenase-deficient fibers) features
were consistent with a diagnosis of mitochondrial disease.
Affected individuals were included if they lived within the geo-
graphical boundary of the North East of England government
office region that is defined by 6 postcodes (NE, DH, DL, SR,
TS, and TD) and includes County Durham, Northumberland,
Newcastle upon Tyne, Sunderland, North Tyneside, Gateshead,
Stockton-on-Tees, South Tyneside, Middlesbrough, Redcar and
Cleveland, Darlington, and Hartlepool. Comprehensive pedi-
gree analysis and family tracing was performed, identifying
other clinically affected individuals and also unaffected family
members at risk of disease. In contrast to our previous study,3
improvements in noninvasive testing4,5 have allowed us to
include elderly individuals, beyond working age, where a posi-
tive genetic diagnosis was confirmed.
Ascertainment of Clinically Affected Adults with
Disease Due to mtDNA Point Mutations,
Deletions, or Duplications, or nDNA Mutations
Adopting our previous ascertainment criteria,3 adults exhibiting
signs and symptoms consistent with a confirmed molecular
genetic diagnosis of mitochondrial disease in either the individ-
ual or their pedigree were defined as clinically affected. When-
ever possible, a molecular genetic diagnosis was confirmed in
several tissues including blood, urine, or muscle using estab-
lished quantitative techniques described in detail elsewhere.4,5
Ascertainment of Individuals at Risk for
Development of mtDNA Disease
Comprehensive pedigree data were collected from all affected
individuals, to define individuals at risk for development of
mitochondrial disease. We included both adults and children,
as previously reported,3 and again restricted our evaluation to
first-degree relatives of those patients with definite clinical dis-
ease or asymptomatic individuals known to harbor a familial
pathogenic mutation of mtDNA. Molecular genetic analysis
was confirmed whenever possible.
Statistical Analysis
Population census data for the midyear period of 2011, as
specified by the Office for National Statistics (ONS) of the
United Kingdom,6 was used to derive denominators and calcu-
late the minimum prevalence of both mtDNA and nDNA dis-
ease in adult individuals and the minimum prevalence of
unaffected individuals at risk of developing mtDNA mitochon-
drial disease. Ninety-five percent confidence limits were calcu-
lated for each of these groups as described elsewhere.7
Results
Prevalence of Pathogenic Mutations of Either
mtDNA or nDNA
The minimum point prevalence of clinically affected
adults with mitochondrial disease attributable to either
the mitochondrial or nuclear genome is 12.5 in 100,000
(95% confidence interval (CI)5 11.1–14.1 3 1025),
whereas the prevalence of all pathogenic mutations in
both nDNA and mtDNA is 23 in 100,000 (1 in
4,300; 95% CI5 14.6–34.5 3 1025).
Clinically Affected Individuals with mtDNA
Disease
The regional adult population (>16 years old) figure for
midyear 2011 was 2,134,449,6 representing a 2.2%
increase in the prevalence data denominator over the pre-
ceding decade, since our last epidemiological evaluation
of the prevalence of mtDNA disorders only. This was rel-
ative to an approximately 7% national average change in
UK population size.8 Clinically affected adults with
mtDNA mutations (n5 204) were identified, determin-
ing a minimum point prevalence of 9.6 in 100,000
(95% CI5 8.3–11.0 3 1025), in this population (Table
1). Seventy-eight adults (minimum prevalence5 3.7 3
1025, 95% CI5 2.9–4.6 3 1025) were affected by 1 of
the 3 common Leber hereditary optic neuropathy
(LHON)9 pathogenic mutations: m.1178G>A (n5 43,
minimum prevalence5 2.0 3 1025, 95% CI5 1.5–2.7
3 1025), m.3460G>A (n5 29, minimum preva-
lence5 1.4 3 1025, 95% CI5 0.9–2.0 3 1025), and
m.14484T>C (n5 6, minimum prevalence5 0.3 3
1025, 95% CI5 0.1–0.6 3 1025). The most common,
pathogenic mtDNA point mutation identified was the
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m.3243A>G mutation (n5 74, minimum preva-
lence5 3.5 3 1025, 95% CI5 2.7–4.4 3 1025).
Thirty-one symptomatic adults harboring single large-
scale mtDNA deletions were also identified (minimum
prevalence5 1.5 3 1025, 95% CI5 1.0–2.1 3 1025).
Five individuals (minimum prevalence5 0.2 3 1025,
95% CI5 0.1–0.5 3 1025) were clinically affected by
the m.8344A>G mutation, manifesting as myoclonic
epilepsy with ragged-red fibers (MERRF).10 The remain-
ing affected adults harbored 1 of 10 other mtDNA point
mutations: m.14709T>C (n5 3), m.5816A>G (n5 3),
m.5650A>G (n5 2), m.8993T>C (n5 2), m.1624C>T
(n5 1), m.12258G>A (n5 1), m.8993T>G (n5 1),
m.12283G>A (n5 1), m.12320A>G (n5 1), and
m.10010T>C (n5 1).
At-Risk Individuals with mtDNA Disease
The midyear 2011 population of adults and children in
North East England was 2.6 million.6 We identified 282
individuals at risk for the development of mtDNA disease.












Single mtDNA deletiona 31 1.5 (1.0–2.1) 3 1025 0 0
Primary LHON mutations
m.3460G>A, MT-ND1 29 1.4 (0.9–2.0) 3 1025 36 1.4 (1.0–1.9) 3 1025
m.11778G>A, MT-ND4 43 2.0 (1.5–2.7) 3 1025 69 2.7 (2.1–3.4) 3 1025
m.14484T>C, MT-ND6 6 0.3 (0.1–0.6) 3 1025 10 0.4 (0.2–0.7) 3 1025
Subtotal 78 3.7 (2.9–4.6) 3 1025 115 4.4 (3.7–5.3) 3 1025
mt-tRNA point mutations
m.1624 C>T, MT-TV 1 0.05 (0.0–0.3) 3 1025 0 0
m.3243A>G, MT-TL1 74 3.5 (2.7–4.4) 3 1025 115 4.4 (3.7–5.3) 3 1025
m.5650A>G, MT-TA 2 0.1 (0.0–0.3) 3 1025 3 0.1 (0.0–0.3) 3 1025
m.5816A>G, MT-TC 3 0.1 (0.0–0.4) 3 1025 0 0
m.8344A>G, MT-TK 5 0.2 (0.1–0.5) 3 1025 12 0.5 (0.2–0.8) 3 1025
m.10010T>C, MT-TG 1 0.05 (0.0–0.3) 3 1025 0 0
m.12258G>A, MT-TS2 1 0.05 (0.0–0.3) 3 1025 12 0.5 (0.2–0.8) 3 1025
m.12283G>A, MT-TL2 1 0.05 (0.0–0.3) 3 1025 0 0
m.12320A>G, MT-TL2 1 0.05 (0.0–0.3) 3 1025 4 0.2 (0.0–0.4) 3 1025
m.14709 T>C, MT-TE 3 0.1 (0.0–0.4) 3 1025 19 0.7 (0.4–1.1) 3 1025
Subtotal 92 4.3 (3.5–5.3) 3 1025 165 6.3 (5.4–7.4) 3 1025
mt-mRNA point mutations
m.8993T>C, MT-ATP6 2 0.1 (0.0–0.3) 3 1025 0 0
m.8993T>G, MT-ATP6 1 0.05 (0.0–0.3) 3 1025 2 0.1 (0.0–0.3) 3 1025
Subtotal 3 0.1 (0.0–0.4) 3 1025 2 0.1 (0.0–0.3) 3 1025
Total 204 9.6 (8.3–11.0) 3 1025 282 10.8 (9.6–12.2) 3 1025
aDenotes sporadic mutations (all others are maternally inherited).
CI5confidence interval; LHON5Leber hereditary optic neuropathy; MT-ATP65mitochondrial ATP synthase F0 subunit 6;
MT-ND15mitochondrial NADH dehydrogenase subunit 1; MT-ND45mitochondrial NADH dehydrogenase subunit 4; MT-
ND65mitochondrial NADH dehydrogenase subunit 6; MT-TA5mitochondrial tRNA alanine; MT-TC5mitochondrial tRNA
cysteine; MT-TE5mitochondrial tRNA glutamic acid; MT-TG5mitochondrial tRNA glycine; MT-TK5mitochondrial tRNA
lysine; MT-TL15mitochondrial tRNA leucine 1; MT-TL25mitochondrial tRNA leucine 2; MT-TS25mitochondrial tRNA ser-
ine 2; MT-TV5mitochondrial tRNA valine.
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This equates to a minimum point prevalence of 10.7 in
100,000 (95% CI5 9.6–12.2 3 1025; see Table 1).
Clinically Affected Individuals with nDNA
Disease
We identified 62 clinically affected individuals with
nDNA disease, and this equates to a minimum point
prevalence of 2.9 in 100,000 (95% CI5 2.2–3.7 3
1025; Table 2). Recessive mutations in SPG7 (spastic
paraplegia 7) and dominant mutations in PEO1 (progres-
sive external ophthalmoplegia 1) were the most common
pathogenic nDNA mutations identified in clinically
affected individuals (SPG7: minimum prevalence5 0.8
3 1025, 95% CI5 0.5–1.3 3 1025; PEO1: minimum
prevalence5 0.7 3 1025, 95% CI5 0.4-1.2 3 1025).
Mutations in OPA1 (optic atrophy 1) caused multisyste-
mic neuromuscular disease in 8 adults in addition to vis-
ual failure (minimum prevalence5 0.4 3 1025, 95%
CI5 0.2–0.7 3 1025). Only autosomal recessive POLG
(polymerase gamma) mutations were identified in the
region, and these caused clinically overt disease in 6 indi-
viduals. A further 3 individuals were found to harbor a
single pathogenic mutation. Dominant mutations in
RRM2B (ribonucleotide reductase M2 B [TP53 induci-
ble]) caused clinically overt disease in 5 adults (minimum
prevalence5 0.2 3 1025, 95% CI5 0.1–0.5 3 1025).
Only 5 clinically affected adult patients with progressive
external ophthalmoplegia (PEO) and multiple mtDNA
deletions in muscle remained genetically undetermined
(minimum prevalence5 0.2 3 1025, 95% CI5 0.1–
0.5 3 1025). The remaining 6 clinically affected individ-
uals harbored mutations in the following nuclear
genes: DNM2 (dynamin 2; n5 1), SDHA (succinate
dehydrogenase complex, subunit A; n5 2), ETFDH
(electron-transferring-flavoprotein dehydrogenase; n5 1),
and TRIT1 (tRNA isopentenyltransferase 1; n5 2; see
Table 2).
Discussion
The implementation of noninvasive diagnostic methods
and advances in next generation sequencing techniques
continue to transform our diagnostic approach to mito-
chondrial disorders.11,12 Yet despite these significant
advances in our understanding of the molecular basis of
mitochondrial disease, making a comprehensive diagnosis
still remains a formidable task. This is in part due to the
recognition of a rapidly expanding spectrum of clinical
features and to the sheer diversity of genetic mutations
adversely affecting mitochondrial function, emphasizing
the fundamental importance of fastidious clinical and
biochemical characterization of patients. Such deep phe-
notyping not only is important from a diagnostic per-
spective, but may also improve our understanding of the
often complex relationship between genotype and pheno-
type. Understanding these mechanistic intricacies may
provide the key to determining effective future treat-
ments and guide clinical prognosis and prevention strat-
egies for mitochondrial disease. Appropriate case
ascertainment and correct disease diagnosis remain cen-
tral determinants of validity in the epidemiologic evalua-
tion of mitochondrial disease prevalence. This in turn is
fundamental to assessing current and projected cost-of-
illness needs of mitochondrial diseases for individuals
and society as a whole. This is particularly relevant at
present because of the development of new in vitro fertil-
ization–based techniques13 that could prevent the trans-
mission of mtDNA disease and thus reduce patient and
societal disease burden.
We have endeavored to accurately document the min-
imum prevalence of symptomatic nDNA mutations and
symptomatic and asymptomatic mtDNA mutations causing
mitochondrial diseases. The inclusion of pathogenic muta-
tions of the nDNA, as well as mutations of the mtDNA,
represents a significant evolution of our understanding of
the social impact of these heterogeneous disorders. As a
TABLE 2. Prevalence Estimate for Nuclear Gene







SPG7, ar 17 0.8 (0.5–1.3) 3 1025
PEO1, ad 15 0.7 (0.4–1.2) 3 1025
OPA1, ad 8 0.4 (0.2–0.7) 3 1025
POLG, ar 6 0.3 (0.1–0.6) 3 1025
RRM2B, ad 5 0.2 (0.1–0.5) 3 1025
SDHA, ad 2 0.1 (0.0–0.3) 3 1025
TRIT1, ar 2 0.1 (0.0–0.3) 3 1025
DNM2, ad 1 0.05 (0.0–0.3) 3 1025
ETFDH, ar 1 0.05 (0.0–0.3) 3 1025
Genetically
undetermined
5 0.2 (0.1–0.5) 3 1025
Total 62 2.9 (2.2–3.7) 3 1025
ad5 autosomal dominant; ar5 autosomal recessive;
CI5 confidence interval; DNM25 dynamin 2;
ETFDH5 electron-transferring-flavoprotein dehydrogenase;
OPA15 optic atrophy 1; PEO15 progressive external oph-
thalmoplegia 1 protein; POLG5 polymerase gamma;
RRM2B5 ribonucleotide reductase M2 B (TP53 inducible);
SDHA5 succinate dehydrogenase complex, subunit A;
SPG75 spastic paraplegia 7; TRIT15 tRNA isopentenyl-
transferase 1.
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whole, mitochondrial disorders are among the commonest
inherited neurological disorders. As individual entities, how-
ever, each genotype or phenotype represents just one facet
of extremely rare disorders that pose difficult challenges in
recognition, diagnosis, and ultimately treatment.
The minimum point prevalence figure for all clini-
cal disease due to mtDNA mutations in this study is
comparable with our previously published point preva-
lence of 1 in 5,0003; reflecting the stability of mtDNA
disease prevalence both geographically and over time.
This also reflects the relative stability of the population
of the North East, where ONS census data8 showed only
a 2.2% increase in the regional population numbers
compared to a 7% increase in national figures in the
intervening decade. The m.3243A>G mutation remains
the most prevalent pathogenic mtDNA point mutation,
being found in 25 pedigrees with a point prevalence of
7.8/100,000, comparable to that of in-region figures for
Mendelian-inherited facioscapulohumeral muscular dys-
trophy.14 The prevalence of LHON remains stable; this
is the most prevalent mtDNA disorder overall (point
prevalence for affected LHON mutations of 3.65 per
100,000; carrier frequency of the 3 common LHON
mutations of 4.42 per 100,000, with familial clustering
evident, m.11778G>A: 12 pedigrees, m.3460G>A: 5
pedigrees, m.14484T>C: single pedigree; see Table 1).
MERRF related to the m.8344A>G mutation remains a
rare form of mitochondrial disease (0.7/100,000) in this
region, similar in frequency to the m.14709T>C15,16
mutation (0.8/100,000). Thirty-one affected individuals
with single large-scale deletions of mtDNA were identi-
fied. All were considered to be predominantly sporadic
events with no at-risk individuals identified. However, we
do acknowledge that maternal transmission may occur,17
and the advent of a prediction tool,18 providing guidance
to the patient and clinician about prognosis and risk of
transmission, may alter this approach in the future. We
identified 2 other pathogenic mutations, in at-risk indi-
viduals. These included 2 mtDNA point mutations,
m.13094T>C and m.4300A>G, in whom the index
cases were deceased at the time of analysis but other at-
risk family members were known to live in region. These
data exemplify the importance of fastidious family trac-
ing and continued clinical surveillance.
Mutations in nDNA genes affect function of the
mitochondrial respiratory chain in a variety of ways,
including: synthesis, assembly, or chaperoning of individ-
ual components of the mitochondrial respiratory chain;
synthesis, maintenance, repair, and translation of mito-
chondrial DNA; and the processes of mitochondrial fission
and fusion, which maintain mitochondrial networks.
Nuclear mutations account for overt disease in 2.9 per
100,000 of the adult population in the North East of
England, approximately one-third of the prevalence for
mtDNA mutations. To date, 14 nuclear encoded genes,
TYMP (thymidine phosphorylase), SLC25A4 (solute car-
rier family 25 [mitochondrial carrier; adenine nucleotide
translocator], member 4), POLG, PEO1, OPA1, POLG2,
RRM2B, TK2 (thymidine kinase 2), DGUOK (deoxygua-
nosine kinase), MPV17 (mitochondrial inner membrane
protein), MGME1 (mitochondrial genome maintenance
exonuclease), DNA2 (DNA replication helicase/nuclease
2), SPG7, and AFG3L2 (AFG3-like AAA ATPase 2),19,20
have been reported to be associated with ophthalmoparesis
and multiple mtDNA deletions in muscle in adult onset
PEO patients. Notably, mutations in SPG7 (4/100,000)
and PEO1 (3/100,000), followed by OPA1 (1/
100,000) and RRM2B (0.9/100,000) have emerged as
major causes of adult mitochondrial disease. Recessive
mutations in POLG (0.6/100,000) are also emerging as an
important cause of mitochondrial disease in the North
East of England. Delineation of an at-risk group of indi-
viduals harboring single pathogenic mutations in POLG is
important, even in nonconsanguineous families. Given the
relatively common prevalence of pathogenic POLG muta-
tion heterozygosity in European populations and the
potential severity of the phenotype due to recessive muta-
tions, the provision of genetic counseling to individuals
and their partners should be made, even where the risks
to future offspring are small. Less than 10% of adult
patients with PEO and muscle restricted mtDNA dele-
tions remain genetically undetermined, reflecting recent
advances in diagnostic yield from implementation of next
generation sequencing and deep clinical phenotyping of all
patients attending our center.
Inherent difficulties exist in the calculation of those
at risk of nDNA-related mitochondrial disease because of
the heterogeneous nature of inheritance patterns of
nDNA mutations, variability in disease penetrance and
clinical expression, and with the recent advent of next
generation sequencing, a recognition of the rapidly
expanding number of nDNA mutations causing mito-
chondrial disease. Accepting such limitations, and imple-
menting the same criteria to determine individuals at risk
of mtDNA-related mitochondrial disease, we would con-
servatively estimate that a minimum of 5.9 in 100,000
(154 individuals; 95% CI5 5.0–6.9 3 1025) are poten-
tially at risk of nDNA-related mitochondrial disease
(Supplementary Table).
Comparison with point prevalence figures for mito-
chondrial disorders in other regions remains difficult.
These current results for mtDNA mutations are similar
to that reported previously in adult patients with mito-
chondrial disease in the North East of England a decade
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earlier and as such act as comparative data.3 Although
the frequency of mtDNA mutations remain stable in our
patient cohort, the point prevalence for the m.3243A>G
mutation remains significantly lower than the frequency
reported by Majamaa et al.21 The reasons for this remain
unclear. However, given that the point prevalence figures
remain stable in the intervening decade in this English
cohort, the genetic background and population structure
may play a more significant role than study design in
creating variability in prevalence rates than originally
purported.3 In addition, the impact of familial clustering
on prevalence frequency is more marked in the rare
forms of both mtDNA and nDNA and may serve as a
confounding factor of the estimated minimum prevalence
rates of these extremely rare disorders. The almost
homogenous white English ethnic profile and lower rates
of parental consanguinity in the North East of England
compared with the ethnically diverse conurbations of
North, Central, and East Midlands and South East Eng-
land will also influence the prevalence rates we have
observed.22 This is particularly pertinent to pediatric
mitochondrial disease, where recessive mutations in
nDNA are more often the genetic etiology.
It is clear from this detailed population study of
adult patients with mitochondrial disease that physicians
recognize the significant risk of disease posed to individu-
als who have family members diagnosed with transmissi-
ble forms of mitochondrial disease. Moreover, we would
suggest that family history alone serves as a surrogate
marker for the development of mtDNA-related mito-
chondrial disease.
Conclusion
This rigorous cross-sectional study benefiting from
improved case ascertainment and diagnosis over the past
decade indicates that adult mitochondrial diseases are
among the most prevalent groups of inherited neurolog-
ical disorders, affecting up to 1 in 4,300 adults in the
United Kingdom. Although we have documented a rela-
tively stable prevalence rate for mtDNA mutations over
time, it seems likely that an improved understanding of
nuclear phenotypes and advances in next generation
sequencing technologies including whole exome and
whole genome sequencing are likely to lead to an
increased recognition of mitochondrial disease attribut-
able to mutations of the nuclear genome. However,
given that <10% of nuclear phenotypes in this cohort
remain genetically undetermined, this figure is unlikely
to change significantly, unless the perceived phenotypic
spectrum is also expanded. Combined, these findings
will facilitate more robust assessment of the level of
services and financial investment required to provide
early detection, prevention, and treatment of mitochon-
drial diseases.
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